The FDA granted accelerated approval to Dizal Pharmaceutical's sunvozertinib (Zegfrovy) for non-small-cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, marking a targeted oral treatment option following chemotherapy. Concurrently, Regeneron Pharmaceuticals received FDA nod for their bispecific antibody Lynozyfic (linvoseltamab) for relapsed and refractory multiple myeloma, offering dosing flexibility that differentiates it from existing therapies. Complementing these approvals, Thermo Fisher's Oncomine Dx Express Test was cleared as a companion diagnostic for Zegfrovy, facilitating patient identification through next-generation sequencing.